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Abstract
Background Oculopharyngeal muscular dystrophy (OPMD) is a late-onset muscle disease affecting one per 80 000 of the
general population characterized by profound dysphagia and ptosis, and limb weakness at later stages. Affected muscles
are characterized by increased fibrosis and atrophy. Myostatin is a negative regulator of muscle mass, and inhibition of
myostatin has been demonstrated to ameliorate symptoms in dystrophic muscles.
Methods In this study, we performed a systemic delivery of a monoclonal antibody to immunologically block myostatin in
the A17 mouse model of OPMD. The mice were administered a weekly dose of 10 mg/kg RK35 intraperitonially for 10 weeks,
following which histological analyses were performed on the samples.
Results This treatment significantly (P < 0.01) improved body mass (11%) and muscle mass (for the tibialis anterior and
extensor digitorum longus by 19% and 41%) in the A17 mice treated with RK35 when compared to saline controls. Similarly,
a significantly (P < 0.01) increased muscle strength (18% increase in maximal tetanic force) and myofibre diameter
(17% and 44% for the tibialis anterior and extensor digitorum longus), and reduced expression of markers of muscle fibrosis
(40% reduction in area of expression), was also observed. No change in the density of intranuclear inclusions (a hallmark of
disease progression of OPMD) was however observed.
Conclusions Our study supports the clinical translation of such antibody-mediated inhibition of myostatin as a treatment
of OPMD. This strategy has implications to be used as adjuvant therapies with gene therapy based approaches, or to stabilize
the muscle prior to myoblast transplantation.
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Introduction
Oculopharyngeal muscular dystrophy (OPMD) is a rare late-
onset muscular dystrophy characterized by progressive
weakening of the extraocular and pharyngeal muscles, man-
ifesting as ptosis and dysphagia, and at later stages of the
disease as a weakening of proximal limb musculature.1 The
disease is caused by mutations in the poly(A)-binding protein
nuclear 1 (PABPN1) gene that introduces an abnormal
expansion of polyalanine-encoding (GCN)n trinucleotide re-
peats in the coding region of exon 1. PABPN1 plays crucial
roles in regulating the poly(A) tail length on mRNAs,2,3
controlling the use of alternative polyadenylation sites,4,5
influencing pre-mRNA splicing,6,7 and also processing of
long non-coding RNA (lncRNAs)8 and small nucleolar RNA
(snoRNA).9 It also has an important role in poly(A)-mediated
RNA decay or export from the nucleus2 and in RNA
hyperadenylation.10
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Repeat alanine expansions with 11–18 repeats lead to a
mutant expanded PABPN1 protein (expPABPN1), which
causes misfolding, and subsequent accumulation of intranu-
clear aggregates in muscles.11 The aggregates sequester
wild-type PABPN1 among other essential components of
the cell, thereby dysregulating essential functions of the
cell.12–20 Interestingly, it has been shown that PABPN1 ex-
pression in muscles declines with age in healthy individuals,
with OPMD patients presenting molecular signatures of
premature ageing.12,21 Global approaches have generated a
body of evidence—including mitochondrial defects, altered
RNA metabolism, specific oxidative fibre atrophy, and in-
creased proteasome activity—suggesting a premature ageing
in OPMD muscles. This has also been implicated in the
comparison of the molecular signature of OPMD patients
and models of muscle ageing.12 Altogether these data
strongly suggest common features between OPMD and age-
ing. No cure currently exists for the disease; to correct ptosis
and dysphagia, patients undergo surgical procedures that
partially alleviate the symptoms. Recent clinical efforts have
however shown promise with myoblast transplantation22
and small molecule drug therapies.23,24
Myostatin acts as a negative regulator of muscle mass, and
naturally occurring myostatin null mutants (such as the
Piedmontese cattle, Texel sheep, and the bully whippet
dogs) display a remarkable hypermuscular phenotype.25
Myostatin signalling primarily occurs via the interaction
of the activin receptor II B and bone morphogenetic
protein pathways, with other pathways such as the IGF-1,
p21/Cdk, and Wnt signalling are known to interact with
myostatin signalling.25–27 Inhibition of myostatin has been
reported to increase muscle mass and myofibre size
(by cytoplasmic growth27). A large number of strategies
(involving propeptide, gene therapy, gene editing, ligand
traps, and monoclonal antibodies) have been investigated
to attenuate myostatin activity in both preclinical and clinical
settings,28–34 especially in cases of cachexia, sarcopenia,
muscular atrophy, and other muscular dystrophies such as
Duchenne muscular dystrophy (DMD).35–40 An anti-myostatin
strategy, while not targeting the underlying genetic cause of
the disease, may lead to an improvement in the quality of life
of patients by delaying the onset of locomotion and atrophy
related disability. Though early clinical trials in DMD, or
Becker’s muscular dystrophy with the first generation anti-
myostatin antibody MYO-029 displayed limited therapeutic
potential,29 other therapeutic candidates have been since
developed. The anti-myostatin antibody RK35 developed
by Pfizer presents a next generation hybridoma and
has been previously tested in models of amyotrophic
lateral sclerosis, nemaline myopathy, and DMD, where
it demonstrated efficacy in improving muscle mass and
function.32,41–43 The humanized equivalent of RK35
(Domagrozumab) is currently in clinical testing in DMD
patients following a Phase 1 study in healthy volunteers.32
To our knowledge, this is the first report to examine the
effect of inhibiting myostatin in a model of OPMD.
The A17 transgenic mouse over-expresses bovine
expPABPN1 specifically in skeletal muscle,44 and it is the most
commonly used murine model of OPMD. This mouse exhibits
loss of body mass, muscle atrophy, decreased muscle
strength, transcriptomic dysregulation, and accumulation of
insoluble aggregates in myonuclei.13,17 Here, we show that
treatment of OPMD mice with the murine anti-myostatin
monoclonal antibody RK35, while not affecting accumulation
of intranuclear aggregates, prevents loss of body mass,
muscle atrophy, and muscle strength and reduces deposition
of fibrotic collagen proteins, which are relevant endpoints for
a therapy targeting OPMD. Overall, our data support the
clinical translation of myostatin inhibition to ameliorate
symptoms of OPMD.
Material and methods
Animal handling
A17 and FvB mice were bred in-house, and all mice were
housed individually with food and water ad libitum in a
minimal disease facility at Royal Holloway, University of
London. Individual mice were identified by ear-notching at
about 4 weeks of age, and each mouse was monitored as
per the recommendations of Animals (Scientific Procedures)
Act (1986). Due to the heterozygous nature of the disease
model, the OPMD mice were analysed to confirm the geno-
type by PCR, with primers directed against the bovine
PABPN1 insert (50-GAACCAACAGACCAGGCATC-30 and 50-
GTGATGGTGATGATGACCGG-30). The PCR cycle implemented
initial denaturation at 95°C for 2 min, followed by 40 cycles
of 95°C denaturation, 60°C for annealing, and 72°C for
extension with each step lasting for 30 s. The final extension
was conducted at 72°C for 10 min.17
Male 12-week-old mice were weighed prior to each
injection. Initial body weights were used to evenly distribute
animals among cohorts to ensure equivalent average body
weights prior to the commencement of experimental proto-
cols. In this experiment, we administered the anti-myostatin
blocking antibody RK35 [Pfizer, USA; diluted in sterile saline
(Sigma Aldrich, UK) for a final volume of 200 μL] which was
injected at 10 mg/kg weekly i.p. for 10 weeks into 9 A17 mice
(disease model for OPMD) and 8 FvB (littermate strain
control) mice. A further 10 A17 mice and 9 FvB mice were
administered the vehicle (sterile saline) as a control in the
experiment.
Forelimb grip strength analysis
To assess the forelimb grip strength of the animals, mice
were allowed to rest on an angled mesh assembly, facing
away from the meter (Linton Instrumentation, Norfolk, UK)
and with its hind limbs not in contact with the mesh. A pulling
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force was exerted on the tail of the mouse parallel to the
angle of the mesh, causing the animal to resist with both
forelimbs. The force was recorded as the maximal force over
a period of 30-s, with five observations recorded per day.
To prevent habituation of the mice, the test was performed
over 3 days in 30-s intervals of data collection and rest, over
five observations per day resulting in 15 observations per
mouse. Procedures were performed in accordance with
Treat-NMD protocols.
In situ muscle electrophysiology
At the end of the experiment, muscle function was assessed
using the right tibialis anterior (TA) muscle. A17 and FvB mice
were deeply anaesthetized by using a mix of Hypnorm/
Hypnovel solution (i.p.) and were carefully monitored
throughout the experiment to ensure that there was no
reflex response to toe pinch. The distal tendon of the TA
muscle was dissected from surrounding tissue and tied
with 4.0 braided surgical silk (Interfocus, Cambridge, UK).
The sciatic nerve was exposed and superfluous branches
axotomized, leaving the TA motor innervation via the
common peroneal nerve intact. The foot was secured to a
platform and the ankle and knee immobilized using stainless
steel pins. The TA tendon was attached to the lever arm of
a 305B dual-mode servomotor transducer (Aurora Scientific,
Ontario, Canada) via a custom-made steel s-hook. TA muscle
contractions were elicited by stimulating the distal part of
common peroneal nerve via bipolar platinum electrodes,
using supramaximal square-wave pulses of 0.02 ms (701A
stimulator; Aurora Scientific). Data acquisition and control
of the servomotors were conducted using a Lab-View-based
DMC programme (Dynamic muscle control and Data
Acquisition; Aurora Scientific). Optimal muscle length (Lo)
was determined by incrementally stretching the muscle using
micromanipulators until the maximum isometric twitch force
was achieved. Maximum isometric tetanic force (Po) was
determined from the plateau of the force–frequency relation-
ship following a series of stimulations at 10, 30, 40, 50, 80,
100, 120, and 150 Hz. The specific force (N/cm2) was
calculated by dividing Po by TA muscle cross-sectional
area. Overall cross-sectional area was estimated using
previously established protocols.13
Sample collection and processing
Mice were euthanized 1 week after the last injection of RK35,
and TA, extensor digitorum longus (EDL), and soleus muscles
were harvested, weighed and mounted in O.C.T. compound
(Thermo Fisher Scientific, Leicestershire, UK), frozen in
2-methylbutane (isopentane) chilled with liquid nitrogen,
and stored at 80°C.
Histological and immunohistochemical analysis
Transverse sections of the tissue were sectioned at 10 to 12
different intervals at a thickness of 10 μm, along the length
of the muscle, allowing the maximal cross-sectional area to
be determined, and the sections mounted on coated slides
(VWR International, Leicestershire, UK), and stored at
80°C. Transverse sections of the TA and EDL were air-dried,
fixed, and stained with anti-PABPN1 (rabbit monoclonal,
diluted 1:100, Abcam ab75855, overnight at 4°C), anti-laminin
(rat monoclonal, diluted 1:800, Sigma-Aldrich L0663, 1 h at
room temperature), and anti-collagen VI (rabbit polyclonal,
Abcam ab6588, 1:200, 1 h room temperature) antibodies or
with picosirius red using previously established protocols.13
Slides were stained with DAPI (40,6-diamidino-2-phenylindole,
1μg/ml) to visualize nuclei, and coverslips were mounted
using mounting medium (Vector Labs, California, USA).
Whole muscle images (for laminin based fibre morphometry)
or random fields (for PABPN1 and collagen immunostaining)
were captured using a microscope (Zeiss, Cambridge, UK).
For analysis of fibre morphometry, the median diameter from
1000 or 400 randomly selected fibres were determined
respectively for TA and EDL muscles for each individual
animal analysed. For analysis of succinate dehydrogenase
(SDH) activity, tissue sections were incubated in the dark for
an hour, in a solution of 0.1 M Na2HPO4, 0.1 M NaH2PO4,
0.1 M sodium succinate, and 2.4 mM nitro-blue tetrazolium
(Sigma Aldrich, UK), and random fields were analysed for
the percentage of SDH positive fibres.
Quantitative PCR analysis
Total RNA was extracted from frozen skeletal muscles biop-
sies using Trizol (Invitrogen) according to the manufacturer’s
instructions. RNA samples were quantified using a ND-1000
NanoDrop spectrophotometer (NanoDrop Technologies).
RNA (50–250 ng) was reverse transcribed using M-MLV
reverse transcriptase (Invitrogen) according to the manufac-
turer’s instructions. cDNA was used for quantitative PCR
reaction using SYBR green mix buffer (LightCycler® 480 Sybr
green I Master) in a total of 9 uL reaction volume. PCR
reaction was carried out as follows: 8 min at 95°C followed
by 50 cycles: 15 s at 95°C, 15 s at 60°C, and 15 s at 72°C.
Specificity of the PCR products was checked by melting curve
analysis using the following programme: 65°C increasing by
0.11°C/s to 97°C. The expression level of each mRNA was
normalized to that of murine RPLP0 mRNA (large ribosomal
protein, subunit P0) expression. Expression levels were
calculated according to the DDCt method. Primers were
designed to target Myh2 (50-ACTTTGGCACTACGGGGAAAC-30
and 50-CAGCAGCATTTCGATCAGCTC-30), Myh4 (50-CTTTGC
TTACGTCAGTCAAGGT-30 and 50-AGCGCCTGTGAGCTTGTAAA-
30), and Rplp0 as a housekeeping control (50-GAGGACCTCAC
TGAGATTCGG-30 and 50-TTCTGAGCTGGCACAGTGAC-30).
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Statistical analyses
After checking for the conditions of normality and homosce-
dasticity, a one way analysis of variance (ANOVA) was
performed to compare multiple groups. Multiple comparison
were performed with the Benjamini, Hochberg, and Yekutieli
correction for the false discovery rate (FDR) to correct for
multiple testing used. All descriptive statistical techniques
were performed using GraphPad Prism v7.00 (GraphPad
Software, California, USA).
Results
Anti-myostatin antibody RK35 treatment
significantly reduces loss of body mass and muscle
atrophy in A17 mice
Twelve-week-old A17 (OPMD mice) and FvB (WT; wild-type
strain control) mice were treated by weekly intraperitoneal
(i.p.) injection of RK35 antibody (10 mg/kg in saline) or saline
over a 10-week period. Body mass, which has been correlated
to muscle strength and is considered a rapid and longitudinal
method to follow disease progression,45 was measured
weekly. The treatment was well tolerated, and all mice
grew during the 10-week time treatment (Figure 1A). At the
end of the experiment, saline-treated OPMD mice had
significantly lower body mass than saline-treated WT mice
(8% reduction; P < 0.05). Administration of RK35 antibody
resulted in an increase of 11% (P < 0.01) in the final body
mass of OPMD mice when compared to saline-treated OPMD
mice, normalizing it to that of saline-treated WT control mice
(Figure 1B). In this A17 OPMD model, myopathy induces
muscle atrophy.17,44 As different mammalian muscle fibre
types possess varying sensitivities to this pathophysiological
atrophy, three distinct muscles (TA, EDL, and soleus which
are composed of mixed fibre type, a majority of type IIb
fibres, and a majority of type I fibres, respectively46)
were examined. The muscle mass of both TA and EDL
increased after treatment by about 19% (P < 0.01) and 41%
(P < 0.01), respectively (Figure 1C–D), in A17 mice treated
with RK35 compared with mice treated with saline. The
Figure 1 Treatment with RK35 antibody significantly increases body mass in A17 mice: Mice (n = 8–10) were weighed and administered a weekly reg-
imen of either saline or the RK35 antibody (10 mg/kg i.p.) for 10 weeks from the 12th week of age. (A) The average body mass per group plotted
against weeks shows that body mass increases in all groups of mice. (B) The average body mass at the final week shows that A17 mice treated with
RK35 antibody are heavier than A17 mice treated with saline. TA (C), EDL (D), and soleus (E) were sampled, and mean mass of all muscles were nor-
malized to the initial body mass. Muscle masses of the TA and EDL were increased in both the treated oculopharyngeal muscular dystrophy and control
mice, with no change observed in the soleus. Data presented as mean ± standard error of the mean, with P-values obtained by analysis of variance
after a false discovery rate correction (*P < 0.05 and **P < 0.01). EDL, extensor digitorum longus; TA, tibialis anterior.
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muscle mass of TA and EDL of RK35 treated A17 mice was
either not significantly different to those of wild-type FvB
controls (TA muscles, P > 0.05) or significantly heavier (EDL
muscles, 14% heavier, P < 0.05) (Figure 1C–D). Similar
changes were observed for TA and EDL muscles of treated
FvB mice; TA and EDL muscles of RK35 treated wild-type
FvB mice where 18% (P < 0.01) and 20% (P < 0.01)
heavier than muscles of saline-treated FvB mice, respectively
(Figure 1C–D). Muscle mass of soleus was not affected by
the treatment with RK35 in either A17 or FvB mice (Figure 1E).
This was not unexpected because myostatin null mutants
display minimal change in the contractile properties of
the soleus.47 These data demonstrate that a systemic treat-
ment with clinically relevant doses of RK35 antibody signifi-
cantly increases the body and the muscle masses of the TA
and EDL in OPMD mice.
RK35 treatment improves the histopathology of
oculopharyngeal muscular dystrophy
To further characterize the increase in muscle mass
observed in treated mice, average myofibre size was mea-
sured in TA and EDL muscles. Whole muscle cross sections
were stained with anti-laminin antibodies, blinded, and
analysed for myofibre size assessing the minimum Feret’s
diameter. The average myofibre cross-sectional area of TA
and EDL muscles of A17 mice were 28% (P < 0.001) and
22% (P < 0.001) smaller compared to FvB mice (Figure 2).
Administration of the RK35 antibody in A17 mice resulted
in a significant increase in the average diameter of TA
(17%, P < 0.01) and EDL myofibres (44%, P < 0.001) re-
spectively, when compared to saline-treated A17 mice
(Figure 2A–D).
Figure 2 Treatment with RK35 antibody increases myofibre diameter in oculopharyngeal muscular dystrophy mice: Mice were administered with a
weekly regimen of either saline or the RK35 antibody (10 mg/kg IP) for 10 weeks from 12-week of age. Muscle samples from five randomly selected
mice per group were sectioned and immunostained for laminin. (A) 1000 fibres were randomly selected for the TA, whereas (B) 400 fibres were
randomly selected for the EDL, and the median minimum Feret diameter was analysed. The mice treated with the antibody consistently displayed
an increased myofiber diameter, with the muscle mass of the disease model either normalized to or exceeding the FvB controls. The average median
minimum feret diameter per group was plotted, with bars representing standard error of the mean, with P-values obtained by analysis of variance after
a false discovery rate correction (*P < 0.05 and **P < 0.01). EDL, extensor digitorum longus; TA, tibialis anterior.
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Muscle fibrosis is a distinct histopathological feature of
affected OPMD muscles in humans. To study the effect of a
RK35-mediated myostatin inhibition on collagen protein
deposition and fibrosis in the A17 mouse, TA muscle sections
from RK35 or saline-treated mice were stained with either
picosirius red (to detect collagen proteins I and III) or with
an antibody against collagen VI. TA muscles of saline-treated
A17 have 56% (P < 0.001) increased area of collagen
VI deposition and 51% (P < 0.01) increased deposition of
collagens I and III compared to muscles of age-matched
saline-treated FvB mice (Figure 3A,B). Inhibition of
myostatin in A17 mice reduced deposition of collagen VI in
the TA muscle by 40% (P < 0.001), and of collagens I and
III by 44% (P < 0.01) when compared to saline-treated
A17 mice normalizing the area covered by collagen proteins
to the level observed in wild type mice (Figure 3A–B). One of
the characteristic histopathological hallmarks of OPMD
is the aggregation of expPABPN1 in muscle tissues.1,48
To evaluate if inhibition of myostatin in A17 mice
resulted in any change in the aggregate content, TA muscle
sections from mice treated with RK35 were stained
with antibody to PABPN1 and percentage of myonuclei
with insoluble aggregates calculated. As expected, the
percentage of myonuclei containing aggregates in wild-type
FvB mice was negligible (<1% of observed nuclei) and
significantly higher in the saline-treated A17 mice (36% ±
0.79%, P < 0.001; Figure S1A–F). Administration of RK35
antibody did not change the percentage of myonuclei
containing aggregates in treated A17 (Figure S1A–F). We
additionally analysed the effect of inhibition of myostatin by
the antibody RK35 on myofibre metabolism and fibre type,
using two methodologies: measuring change in expression
levels of SDH and expression of two transcripts related to
myofibre type: Myh2 and Myh4 (coding for myosin type IIa
and type IIb respectively; cDNA generated from a muscle ex-
tract of TA). We report no significant differences observed
Figure 3 Treatment with RK35 antibody reduces collagen deposition in muscles of oculopharyngeal muscular dystrophy mice: Mice were administered
with a weekly regimen of either saline or the RK35 antibody (10mg/kg i.p.) for 10 weeks from 12-week of age. Five randomly selected whole TA muscle
sections from all groups were stained for (A) collagen VI and (B) picosirius red, and five random fields were imaged and analysed for the percentage
area of collagen staining. The mice treated with the antibody consistently displayed a reduced collagen deposition, with the area of collagen in the
disease model normalized to wild-type levels. The average area per group is plotted, bars representing standard error of the mean, with P-values
obtained by analysis of variance after a false discovery rate correction (*P < 0.05 and **P < 0.01). TA, tibialis anterior.
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between the groups studied (Figure S2A–D). These data show
that the anti-myostatin treatment significantly reduces
myofibre atrophy and muscle fibrosis by altering biological
pathways that do not affect the formation of aggregates in
muscles or fibre type of A17 mice.
RK35 mediated increase in muscle mass is
accompanied by an increase in muscle strength
Forelimb grip strength was measured in A17 and FvB mice
treated with the RK35 antibody or saline. The forelimb
strength of the A17 mice was 13% lower (P < 0.05) than that
of FvB control mice which likely reflects the atrophic and
fibrotic condition of OPMD affected muscles (Figure 4A).
The administration of RK35 in A17 mice significantly
increased the forelimb strength by 23% (P < 0.001) when
compared to the saline-treated A17 mice. This increase in
grip strength resulted in mice being equally strong as saline-
treated FvB control mice (Figure 4A). On the contrary, the
treatment with RK35 antibody did not modify the forelimb
strength of treated FvB mice (Figure 4A). Because this in-life
measure is not a pure readout of muscle strength, as it is
dependent upon neurological, anatomical, and behavioural
factors, the direct effect of myostatin inhibition on skeletal
muscle force production was assessed by measuring maximal
tetanic force generated in response to a series of increasing
stimulation frequencies by in situ muscle electrophysiology.
The maximal tetanic force generated by TA muscles of
A17 mice was 55% (P < 0.001) lower than that of FvB
controls (Figure 4B,C). Administration of RK35 antibody to
A17 mice significantly increased the maximum tetanic force
of TA muscles compared to saline-treated A17 mice by 18%
(P < 0.05) while no change in maximum tetanic force was
observed between TA of RK35 treated and saline-treated
FvB mice. Normalizing the maximum tetanic force with the
calculated muscle cross-sectional area yields specific maximal
force, a measurement that expresses the force of the muscle
per unit of area. No difference was observed in specific
maximal force for TA muscles between any of the groups
Figure 4 Treatment with RK35 increases muscle strength in oculopharyngeal muscular dystrophy mice: Mice (n = 8–10) were administered with a
weekly regimen of either saline or the RK35 antibody (10 mg/kg IP) for 10 weeks from 12-week of age. (A) Forelimb grip strength was analysed
and the average of 15 measurements per mouse, per group is plotted, bars representing standard error of the mean, with P-values obtained by anal-
ysis of variance after a false discovery rate correction. (B–D) The left TA from all groups were mounted on a mechanotransducer and the sciatic nerve
was excited (B) average max. force generated at increasing frequencies is plotted. (C) The average max. force generated at 180 Hz is plotted, with bars
representing standard error of the mean. The gross muscle strength of the disease model mice treated with the antibody displayed an increased grip
strength, although a similar effect was not observed in the control mice. (D) Maximal force values were normalized with the muscle cross-sectional
area to obtain specific force of TA at 180 Hz, and no significant differences observed between the groups. Data presented as mean ± standard error
of the mean, with P-values obtained by analysis of variance after a false discovery rate correction (*P < 0.05 and **P < 0.01). TA, tibialis anterior.
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analysed (data not shown). Finally, as the treatment with
RK35 affected the body weight and the muscle mass of A17
mice, we evaluated the locomotor behaviour to exclude any
detrimental effect of such treatment. No change in voluntary
locomotion between the saline-treated and RK35 treated
mice was detected, nor a change was observed between
the A17 and FvB mice (data not shown). Overall, these data
show that in RK35 treated A17 mice the muscle force
increases with the hypertrophic effect and this is reflected in
an improved limb strength.
Discussion
Myostatin is a negative regulator of muscle mass. The efficacy
of myostatin blockade by the monoclonal antibody RK35 has
been examined in the murine models of amyotrophic lateral
sclerosis, DMD, and nemaline myopathy,41–43 and this anti-
body is currently in phase II clinical trial for DMD
(NCT02907619 and NCT02310763). In this study, we tested
the effect of myostatin inhibition to ameliorate atrophic
symptoms in the A17 OPMD mouse model system using this
antibody. The A17 mice co-express a pathological expPABPN1
transgene in skeletal muscles to mimic the disease at a tissue
level. Early studies in the A17 model have reported the onset
of loss of muscle force by 18 weeks of age. To evaluate the
efficacy of myostatin inhibition before the pathological onset
of disease in terms of delaying disease progression, we
treated the A17 disease model with the anti-myostatin anti-
body RK35 for 10 weeks, from the 12th week of age. As pre-
viously shown,17 our study confirmed that A17 mouse model
at 22 weeks of age (i.e. at the end of the treatment) has
lower body and muscle mass as compared to the FvB
age-matched controls. The lower muscle mass was accompa-
nied by an atrophy of the muscles, and an increased level of
observed fibrosis markers resulting in a lower functional
quality of muscles as compared to the saline-treated wild-
type FvB mice. The treatment with RK35 antibody resulted
in the reversal of loss of body mass in the OPMD model.
The increase in body mass was most evident during the first
5 weeks of the 10-week treatment regimen, after which the
difference was maintained. Using the same antibody, a
similar effect in DMD and nemaline myopathy models was
observed by St. Andre et al.43 and Tinklenberg et al.,41
respectively. The increased response to the antibody
(in terms of change in muscle mass) we observed in the EDL
compared to the TA and soleus muscles is likely due to the
myofibrillar metabolic profile of glycolytic fast-twitch fibres
that cause an increased production of myostatin transcripts
and an increased density of the activin receptor II B receptors
to be present in the EDL.47 This observation is particularly
interesting as OPMD disease progression is reported to be
more specific in fast-twitch muscle fibres, such as those
found in the EDL.17The increase in muscle size observed in
muscles of the A17 mice treated with RK35 is promising, as
it indicates that inhibition of myostatin may be a valid strat-
egy to counteract the loss of muscle mass in OPMD human
patients. Skeletal muscles form the most abundant tissue in
the body and maintain the energy balance of the organism
by regulating glucose availability in the blood serum. Indeed,
muscles absorb glucose which are then stored or oxidized
subsequent to a contraction induced/(postprandial secreted)
insulin induced signals. We speculate that this increase in
muscle mass may assist to further attenuate any secondary
effects in systemic metabolism that may arise from muscular
atrophy, by perhaps increasing insulin sensitivity of the
organism.
Muscle fibrosis forms an essential step in both myogenesis
and in muscle regeneration where it helps reforming the
contractile unit from myofibre stumps after damage.49,50
However, in OPMD, the fibrotic deposition is mainly
pathological and it is associated with a defective muscle
functionality perhaps contributing to dysphagia and ptosis
in OPMD subjects. The reduction in the area of fibrotic
collagen deposition in the TA is promising and indicates a
prevention of loss of structural integrity of skeletal muscles.
This might be related to the effect of myostatin inhibition in
inducing apoptosis of fibroblasts.51 Again, the effect of RK35
on fibrosis may be crucially important to preserve and
possibly restore the functionality of affected muscles of
human OPMD subjects.
The increase in muscle mass and the reduction in patholog-
ical fibrosis is correlated to an increase in grip strength and
maximal tetanic force, corresponding to an improvement in
gross muscle function in the treated A17 mice. No such effect
was evident in the treated wild-type FvB mice despite of an
increase in muscle mass. This indicates that the antibody
treatment may be more effective in atrophic muscles than
in healthy muscles most likely because healthy muscles may
have already attained the maximal possible biological
myofibre diameter.
Among the other therapeutic strategies under clinical and
preclinical development for muscular dystrophies, the anti-
myostatin antibody strategy has some advantages. Firstly,
the systemic and non-invasive method of drug administration
can ameliorate symptoms in all affected muscles as opposed
to specific muscles that are targeted by other locally
administered agents (i.e. gene therapy vectors and myoblast
transplantation). Furthermore, monoclonal antibodies are less
costly to produce, easier to attain regulatory approval, and
translate into clinical trials than other gene and cell therapy
approaches.52 This strategy has the potential to be used as
an adjuvant therapy53 of pharmacological treatments cur-
rently in preclinical and clinical development (i.e. trehalose)
or gene therapy13 that target aggregate formation without ad-
dressing the issue of pre-existing muscle atrophy or fibrosis.
An interesting observation relating to the disease condition
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itself revolves around the fact that an improvement in muscle
force and rescue of muscle atrophy was evident without
affecting the number of intranuclear aggregates. While the
exact mechanisms associated with disease progression with
respect to aggregate formation remains to be elucidated,
our results may suggest that the presence of aggregates does
not preclude an increase in muscle hypertrophy. Notably, this
demonstrates that a treatment strategy that does not target
the affect the aggregate formation in muscle might be clini-
cally viable in OPMD. Future experiments can be conducted
in order to elucidate the effect of an anti-myostatin treatment
regimen on the signalling pathways of the disease model. In
conclusion, we report that a systemic administration of an
anti-myostatin monoclonal antibody delays disease progres-
sion in the OPMD mouse model and, as such, is a promising
therapeutic strategy to be explored.
Acknowledgements
The authors wish to thank Jane Owens, Michael St-Andre,
Carl Morris, and other colleagues at Pfizer for providing the
antibody RK35 and for support designing the study. The
authors also wish to acknowledge Martine Oloko for technical
assistance during the course of the study. P.H. also wishes to
thank S. Harish and H. Parameshwaran for their support. The
authors certify that they comply with the ethical guidelines
for authorship and publishing of the Journal of Cachexia,
Sarcopenia and Muscle.54 All data supporting this study is pro-
vided either in the Results section of the manuscript or as
supplementary information accompanying this paper. P.H.,
A.M., C.T., L.P., and G.D. designed the study. P.H., A.M., L.
F., N.L., O.C., and F.R. collected, analysed and interpreted
data. P.H. and A.M. participated in manuscript preparation.
All authors provided manuscript review and revisions.
Online supplementary material
Additional supporting information may be found online in the
Supporting Information section at the end of the article.
Figure S1. Treatment with RK35 does not affect the amount of
intranuclear aggregates: Mice were subject to a weekly regi-
men of either saline or the anti-myostatin RK35 antibody i.p.
for 10 weeks from the 12th week of age till the 22nd week of
age. Five muscle samples from all groups were stained for
bovine PABPN1 after a 1M KCl treatment, and 5 random fields
were imaged and analysed for the percentage number of
positive PABPN1 stains to all myonuclei. The administration
of the treatment regimen did not change the number of
intranuclear aggregates observed. The average density is
plotted, bars representing SEM, with p-values obtained by
ANOVA after a FDR correction (*p<0.05; **p<0.01).
Figure S2. Treatment with RK35 does not affect myofibre type
or myofibre oxidative capacity in the OPMD model mice: Mice
were subject to a weekly regimen of either saline or the anti-
myostatin RK35 antibody i.p. for 10 weeks from the 12th
week of age till the 22nd week of age. Five muscle samples
from the A17 mice treated with saline or RK35 were stained
for SDH activity. Random fields from different regions of the
TA; namely the (a) superficial TA (region around the periphery
of the muscle wherein a higher density of fast-twitch fibres
are found) and (b) deep TA (the central portion of the muscle
having a higher density of slow fibres) were analysed sepa-
rately. The administration of the treatment regimen did not
change the number of SDH positive fibres observed. The per-
centage SDH positive fibres is plotted, bars representing SEM,
with p-values obtained by a t-test (no significant differences
observed between groups). Additionally, a qPCR was per-
formed in order to investigate the transcript levels of the my-
osin heavy chains (c) IIa (encoded by myh2) and (d) IIb
(encoded by myh4), with values normalised to the levels of
RPLP0. The normalised mean abundance of transcripts are
plotted, bars representing SEM, with p-values obtained by
ANOVA after a FDR correction (no significant changes ob-
served between groups).
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